Upgrades
- Alder Biopharmaceuticals (ALDR) upgraded by Morgan Stanley from Underweight to Equal Weight
- Alder Biopharmaceuticals (ALDR) upgraded by UBS from Sell to Neutral
- Splunk (SPLK) upgraded by JPMorgan from Neutral to Overweight
- J Sainsbury (JSAIY) upgraded by UBS from Neutral to Buy
- Novo Nordisk (NVO) upgraded by Citi from Neutral to Buy
- Burlington Stores (BURL) upgraded by UBS from Sell to Neutral
- TJX (TJX) upgraded by UBS from Sell to Neutral
- ConocoPhillips (COP) upgraded by UBS from Neutral to Buy
- PagSeguro Digital (PAGS) upgraded by HSBC from Reduce to Hold
- Tele2 (TLTZY) upgraded by Berenberg from Hold to Buy
- Telia (TLSNF) upgraded by Berenberg from Sell to Hold
- Snap (SNAP) upgraded by Susquehanna from Negative to Neutral
- Ameren (AEE) upgraded by BofA/Merrill from Neutral to Buy
Downgrades
- Alder Biopharmaceuticals (ALDR) downgraded by Needham from Buy to Hold
- Eisai (ESALY) downgraded by Daiwa from Neutral to Sell
- Saipem (SAPMY) downgraded by Exane BNP Paribas from Outperform to Neutral
- Atlas Air (AAWW) downgraded by Susquehanna from Positive to Neutral
- Home Depot (HD) downgraded by Guggenheim from Buy to Neutral
- Raytheon (RTN) downgraded by Bernstein from Outperform to Market Perform
- Dream Global REIT (DUNDF) downgraded by CIBC from Outperformer to Neutral
- The Medicines Co. (MDCO) downgraded by Citi from Buy to Neutral
- EverQuote (EVER) downgraded by BofA/Merrill from Buy to Underperform
- NIC Inc. (EGOV) downgraded by DA Davidson from Buy to Neutral
Upgrades & Downgrades provided by The Fly at http://www.thefly.com. The Fly is a leading digital publisher of real-time financial news. Our financial market experts understand that news impacting stock prices can originate from anywhere, at any time. The Fly team scours all sources of company news, from mainstream to cutting-edge, then filters out the noise to deliver short-form stories consisting of only market moving content. Become an informed investor. Try all of TheFly’s services FREE for 14 days by clicking here.